MYL3 Inhibitors
MYL3 inhibitors belong to a specific chemical class that modulates the activity of the MYL3 gene product. The MYL3 gene encodes for the myosin light chain 3, a crucial component of the myosin motor protein found in muscle cells. Myosin plays a fundamental role in muscle contraction, serving as the molecular motor that drives the sliding of actin and myosin filaments during the contractile process. Inhibitors targeting MYL3 are designed to interact with and disrupt the normal function of myosin, consequently impeding the contractile machinery in muscle cells.
MYL3 inhibitors are tailored to bind selectively to the myosin light chain 3, interfering with its interactions and impeding the normal progression of the contractile cycle. By modulating the activity of MYL3, these inhibitors may have downstream effects on muscle function, potentially influencing cellular processes related to contraction and force generation. Understanding the intricate details of MYL3 inhibition at the molecular level is critical for elucidating the broader physiological consequences and exploring potential applications of these compounds in various contexts. Ongoing research endeavors aim to unravel the precise mechanisms by which MYL3 inhibitors exert their effects, shedding light on the intricate interplay between molecular structures and physiological outcomes in the realm of muscle biology.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Inhibits myosin II ATPase activity, thereby reducing muscle contraction which can indirectly affect MYL3 function. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Inhibits myosin light chain kinase (MLCK) which phosphorylates MYL3, leading to a decrease in myosin regulatory light chain activity. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
Inhibitor of calmodulin, which interacts with MLCK; by inhibiting calmodulin, MLCK activity is reduced and subsequently MYL3 phosphorylation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits ROCK (Rho-associated protein kinase), which phosphorylates and activates MLCK, thus indirectly decreasing MYL3 phosphorylation. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Inhibits protein kinase C, which can phosphorylate MLCK, thereby potentially reducing MYL3 activity. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
Inhibits Ca2+/calmodulin-dependent protein kinase II (CaMKII), which can influence MLCK and MYL3 activity. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Beta-blocker that decreases heart rate and contractility, indirectly affecting MYL3 function in the heart. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker that reduces calcium influx, thus potentially affecting MYL3 function through reduced MLCK activity. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Inhibits protein kinase C, which could reduce the phosphorylation of MLCK and subsequently MYL3. | ||||||
2,3-Butanedione 2-Monoxime | 57-71-6 | sc-203774 sc-203774A sc-203774B sc-203774C | 25 g 100 g 250 g 500 g | $42.00 $78.00 $161.00 $286.00 | ||
Reduces myosin ATPase activity, indirectly affecting MYL3's role in muscle contraction. | ||||||